Innoviva Price to Book Ratio 2010-2024 | INVA

Historical price to book ratio values for Innoviva (INVA) over the last 10 years. The current price to book ratio for Innoviva as of November 04, 2024 is 1.81.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Innoviva Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2024-11-01 19.26 1.81
2024-06-30 16.40 $10.64 1.54
2024-03-31 15.24 $11.21 1.36
2023-12-31 16.04 $10.66 1.50
2023-09-30 12.99 $9.75 1.33
2023-06-30 12.73 $8.51 1.50
2023-03-31 11.25 $8.53 1.32
2022-12-31 13.25 $8.18 1.62
2022-09-30 11.61 $9.19 1.26
2022-06-30 14.76 $8.11 1.82
2022-03-31 19.35 $7.93 2.44
2021-12-31 17.25 $7.56 2.28
2021-09-30 16.71 $7.08 2.36
2021-06-30 13.41 $5.67 2.37
2021-03-31 11.95 $6.87 1.74
2020-12-31 12.39 $5.99 2.07
2020-09-30 10.45 $5.28 1.98
2020-06-30 13.98 $4.86 2.88
2020-03-31 11.76 $4.01 2.94
2019-12-31 14.16 $3.38 4.19
2019-09-30 10.54 $2.80 3.76
2019-06-30 14.56 $2.44 5.98
2019-03-31 14.03 $1.98 7.10
2018-12-31 17.45 $1.57 11.09
2018-09-30 15.24 $-1.07 -14.22
2018-06-30 13.80 $-1.53 -9.03
2018-03-31 16.67 $-2.10 -7.94
2017-12-31 14.19 $-2.38 -5.96
2017-09-30 14.12 $-2.06 -6.84
2017-06-30 12.80 $-2.71 -4.72
2017-03-31 13.83 $-3.06 -4.52
2016-12-31 10.70 $-3.26 -3.29
2016-09-30 10.99 $-3.36 -3.27
2016-06-30 10.53 $-3.26 -3.23
2016-03-31 12.59 $-3.20 -3.93
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.205B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $777.423B 80.52
Novo Nordisk (NVO) Denmark $502.334B 38.34
Johnson & Johnson (JNJ) United States $385.533B 15.64
AbbVie (ABBV) United States $359.539B 18.93
Merck (MRK) United States $258.042B 17.12
Novartis AG (NVS) Switzerland $223.511B 14.86
AstraZeneca (AZN) United Kingdom $221.444B 19.73
Pfizer (PFE) United States $159.177B 10.89
Sanofi (SNY) $135.190B 12.25